Long-Term Treatment with Tenofovir in Asian-American Chronic Hepatitis B Patients Is Associated with Abnormal Renal Phosphate Handling

Digestive Diseases and Sciences

Volumn 60, Issue 2, 2015, Pages 566-572

  Tien, Connie ^a   Xu, Jason J ^a   Chan, Linda S ^b   Chang, Mimi ^a   Lim, Carolina ^a   Lee, Sue ^a   Huh, Brian ^c   Shinada, Shuntaro ^b   Bae, Ho S ^a   Fong, Tse Ling ^a,b  

^a ST VINCENT MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Private Practice   (United States)

Author keywords

Bone mineral density; Entecavir; Kidney disease; Nucleotide analog; Osteoporosis; Proximal renal tubular dysfunction; Tenofovir

Indexed keywords

ENTECAVIR; PHOSPHATE; TENOFOVIR DISOPROXIL; ADENINE; ANTIVIRUS AGENT; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ASIAN AMERICAN; BONE DENSITY; CHRONIC HEPATITIS B; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPOPHOSPHATEMIA; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE DISORDER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; X RAY BONE DENSITOMETER; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; DRUG EFFECTS; ETHNOLOGY; HEPATITIS B, CHRONIC; KIDNEY PROXIMAL TUBULE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; RADIOGRAPHY; RISK FACTOR; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ABSORPTIOMETRY, PHOTON; ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HEPATITIS B, CHRONIC; HUMANS; KIDNEY TUBULES, PROXIMAL; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; OSTEOPOROSIS; PHOSPHATES; PROSPECTIVE STUDIES; RENAL REABSORPTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922073564     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3363-4     Document Type: Article

References (35)

1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.
2. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689–696.
3. Hall AM, Edwards SG, Lapsley M, et al. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis. 2009;54:1034–1042.
4. Hall AM, Hendry BH, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773–780.
5. Dauchy FA, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int. 2011;80:302–309.
6. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867–875.
7. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63–F67.
8. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trial Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791–1801.
9. Brim NM, Cu-Uvin S, Hu SL, O’Bell JW. Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome. AIDS Read. 2007;17:322–328, C3.
10. Bonjoch A, Figueras M, Estany C, et al. Osteoporosis Study Group. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010;24:2827–2833.
11. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482–487.
12. Jones S, Restrepo D, Kasowitz A, et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int. 2008;19:913–918.
13. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49:1591–1601.
14. Perrot S, Aslangul E, Szwebel T, Caillat-Vigneron N, Le Jeunne C. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol. 2009;15:72–74.
15. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825–831.
16. Haskelberg H, Hoy JF, Amin J, et al. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE. 2012;7:e38377.
17. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585.
18. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:941–946.
19. Walton RJ, Bijvoet OLM. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975;2:309–310.
20. Stark H, Eisenstein B, Tieder M, Rachmel A, Alpert G. Direct measurement of TP/GFR: a simple and reliable parameter of renal phosphate handling. Nephron. 1986;44:125–128.
21. Brodehl J, Krause A, Hoyer PF. Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol. 1988;2:183–189.
22. Yenice N, Gümrah M, Mehtap O, Kozan A, Türkmen S. Assessment of bone metabolism and mineral density in chronic viral hepatitis. Turk J Gastroenterol. 2006;17:260–266.
23. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.
24. Rodriguez Novoa S, Garcia-Samaniego J, Calleja JL, et al. Altered underlying tubular function in HBV monoinfected patients receiving nucleos(t)ide analogs in a real-world setting: preliminary findings of MENTE study. Hepatology. 2013;58:676A.
25. Norden AG, Lapsley M, Unwin RJ. Urine retinol-binding protein 4: a functional biomarker of the proximal renal tubule. Adv Clin Chem. 2014;63:85–122.
26. Vigano M, Lampertico P, Mangia G, et al. Incidence and clinical consequences of reduced tubular phosphate reabsorption in naïve chronic hepatitis B patients either untreated or treated with tenofovir for 2 years in a field practice study. Hepatology. 2013;58:678A.
27. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205–2215.
28. Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2012;35:1317–1325.
29. Gracey DM, Snelling P, McKenzie P, Strasser SI. Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther. 2013;18:945–948.
30. Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011;55:1235–1240.
31. Martin M, Vanichseni S, Suntharasamai P, et al. Renal function of participants in the Bangkok Tenofovir Study-Thailand, 2005–2012. Clin Infect Dis. 2014; [Epub ahead of print].
32. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.
33. Brown TT, Qaquish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165–2174.
34. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS ONE. 2011;6:e23688.
35. Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol. 2005;11:1843–1847.